ZED-1227 is under clinical development by Zedira and currently in Phase II for Celiac Disease. According to GlobalData, Phase II drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ZED-1227 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZED-1227 overview
ZED-1227 is under development for the treatment of celiac disease and Non Alcoholic Fatty Liver Disease (NAFLD). The drug candidate is administered orally in the form of the capsule. The drug candidate acts by targeting transglutaminase. It is a peptidomimetic agent.
Zedira overview
Zedira is a clinical-stage biotechnology company that develops and markets specialty reagents, small molecule drug candidates and diagnostics in the transglutaminase field. The company provides products such as transglutaminases, microbial transglutaminase, assays and substrates, inhibitors, antibodies, proteases, transglutaminase labeling, blood coagulation, cereal proteins and celiac disease products. It offers services including the determination of microbial transglutaminase activity, gluten and gliadin content in food preparations, production of transglutaminases from animal species, modification of transglutaminases, development of transglutaminase assays and others. The company also offers specialty reagents for transglutaminase-related research and development. Zedira is headquartered in Darmstadt, Hessen, Germany.
For a complete picture of ZED-1227’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
